4XC1.F · KalVista Pharmaceuticals, Inc

-

Please sign in to comment on 4XC1.F

1 Comment

Admin

5 years, 2 months ago

KalVista Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 0.3% below its 200 day moving average.

From a valuation standpoint, the stock is 91.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 117.4.

KalVista Pharmaceuticals, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.

Its net income has dropped by 8.1% to $-10M since the same quarter in the previous year.

Finally, its free cash flow grew by 42.0% to $-8M since the same quarter in the previous year.

Based on the above factors, KalVista Pharmaceuticals, Inc gets an overall score of 2/5.

Exchange	F
CurrencyCode	EUR
ISIN	US4834971032
Sector	Healthcare
Industry	Biotechnology

PE Ratio	None
Dividend Yield	None
Beta	-0.11
Market Cap	1B

ABOUT

KalVista Pharmaceuticals, Inc

As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. It offers sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE), and an oral Factor XIIa inhibitor program. KalVista Pharmaceuticals, Inc. was formerly known as KalVista Pharmaceuticals Ltd. and changed its name to KalVista Pharmaceuticals, Inc. in November 2016. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts. As of June 11, 2026, KalVista Pharmaceuticals, Inc. operates as a subsidiary of Chiesi Farmaceutici S.p.A.

4XC1.F · KalVista Pharmaceuticals, Inc

-

KalVista Pharmaceuticals, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest KalVista Pharmaceuticals, Inc using a moving average strategy